GEHC GE HealthCare Technologies Inc. Insider Trading

Director Kevin Lobo purchases 10,000 shares of GEHC at $64.18; stock down 28.5% from 52-week high of $89.77

Kevin Lobo, a Director at GE HealthCare Technologies Inc., purchased 10,000 shares at $64.18 on 2026-05-22, increasing his holdings from 4,363 shares to 14,363 shares (+229.2% net change). The transaction occurred at a price 28.5% below the 52-week high of $89.77, within a 52-week range of $58.75–$89.77, and follows a 23.6% decline over the prior 90 days. The company's fundamentals remain solid with $5.1B in quarterly revenue, $389.0M net income, and a P/E of 15.28. However, Lobo's cross-ticker track record shows a 0.00% well-timed rate on 7 prior open-market sells (average 90d return +8.2%), indicating his historical sales have not preceded declines. The purchase's significance is moderated by the absence of any structural flag indicating this is a discretionary conviction-driven buy versus a routine portfolio action.

Director Rodney Hochman buys 1,618 shares in first open-market purchase; stock down sharply amid cluster buying by 7 insiders in two weeks.

Director Rodney Hochman made his first open-market purchase at GE HealthCare, buying shares after prior Form 4 activity consisted entirely of stock-based compensation exercises and grants. This marks a deliberate choice to deploy personal capital into the company at a time when the stock trades well below its 52-week high, having declined notably over the past three months. The purchase occurs within a two-week window in which seven insiders at GEHC have bought shares, a pattern that suggests broad-based opportunistic buying rather than a single director's isolated decision. The company remains profitable with steady revenue growth and a reasonable valuation, providing a financial backdrop that makes the timing of multiple insider purchases noteworthy. The combination of Hochman's first-time open-market buy in a cluster context, paired with the stock's weakness, warrants tracking whether this signals an inflection point or simply reflects insiders taking advantage of a temporary dip.

Director Phoebe Watkin buys $63K in GEHC shares amid stock weakness, first open-market purchase after prior sales; 6 insiders buying within 14 days.

Director Phoebe Watkin has made her first open-market purchase in the three-year record, breaking a pattern of stock-based compensation and prior open-market sales. She acquired shares at prices well below the 52-week high, a typical window for insider activity. The purchase coincides with a notable cluster: six insiders bought GE HealthCare shares within a 14-day window, a material concentration of insider buying activity. GE HealthCare remains profitable with growing revenue and trades at a reasonable valuation multiple, providing a fundamental backdrop of operational stability. This filing is worth tracking because it marks a shift in Watkin's behavior and occurs as part of a broader wave of insider buying, though the individual transaction size is modest.

Director H. Lawrence Culp Jr. purchases $5M of GEHC shares; part of 5-insider buying cluster in 14-day window

H. Lawrence Culp Jr., a director of GE HealthCare, committed over $5 million to purchase shares, more than doubling his holdings in a single transaction. This purchase is not isolated—it's part of a coordinated buying pattern with five insiders acquiring shares within a two-week window, which suggests board-level or management alignment on the company's near-term prospects. GE HealthCare remains a profitable company with stable revenue growth and positive earnings, providing a fundamentally sound backdrop for the insider activity. When a sitting director puts substantial personal capital into the stock alongside multiple peers doing the same, it typically reflects confidence in valuation or near-term catalysts, though the cluster itself makes it difficult to isolate Culp's individual conviction from broader insider sentiment.

Director William J Stromberg purchases 1,000 GEHC shares; part of 4-insider buying cluster in two-week window

Director William J Stromberg bought a meaningful stake in GE HealthCare, increasing his holdings by 7 percent through open-market purchase. This trade is part of a broader insider buying cluster, with three other insiders purchasing shares within a two-week window—a pattern that often signals coordinated conviction at the board level rather than individual conviction alone. The company itself is profitable with growing revenue, providing a fundamentally solid backdrop for insider accumulation. When multiple board members are stepping up to buy at the same time, it typically reflects confidence that current valuations represent opportunity rather than a warning sign, making this cluster particularly noteworthy for investors evaluating the company's near-term outlook.

CFO James Saccaro bought 3,310 shares of GEHC at $60.60 on 2026-05-01 (total $200.6K); 2 other insiders also bought in past 14 days.

James Saccaro, GE HealthCare's Chief Financial Officer, purchased 3,310 shares for $200,585.01, increasing his holdings from 84,161 to 87,471 shares. This purchase is part of a cluster pattern—2 other insiders also bought within the past 14 days—indicating coordinated insider activity at the company. The stock has declined sharply: -30.8% from its 52-week high of $88.16 and -15.2% over the past 30 days, though it remains near mid-point of its 52-week range at current price of $61.03. Fundamentals remain intact with net income of $389,000,000.00 and annual revenue growth of +4.8%, though the company's P/E of 14.53 and market cap of $27,762,045,699.58 should be understood in context of recent price weakness. The cluster buy pattern warrants investor attention as multiple executives are accumulating shares at depressed levels.

GE HealthCare CEO Peter Arduini buys ~4,200 shares on open market amid stock pullback from highs

Peter Arduini, the President and CEO of GE HealthCare, purchased over 4,100 shares on the open market, representing a meaningful addition to his holdings in the company he runs. This transaction stands out because it comes while the stock is trading significantly below its recent highs after a sustained pullback—typically the moment when insider conviction becomes most credible, since executives are deploying their own capital into a weakened position rather than piling in during euphoria. GE HealthCare itself remains a solidly profitable business with consistent revenue growth and reasonable valuation, suggesting the CEO is not buying a deteriorating company. Arduini's direct operational knowledge of the business combined with his willingness to increase exposure at a depressed price level sends a meaningful vote of confidence that current market sentiment has moved too far pessimistic relative to the underlying business quality.

GE HealthCare GC Frank R Jimenez buys 1,750 shares at $60.45; prior GEHC purchase +8.0% in 90 days, stock now -31.0% from 52-week high.

Frank R Jimenez, the General Counsel and Corporate Secretary, purchased 1,750 shares of GEHC at $60.45 on 2026-04-30, growing his holdings to 93,932 shares. His prior open-market purchase at this ticker (2024-05-01) realized a 90-day return of +8.0%, indicating a historically constructive entry point. Against that backdrop, the current price of $60.84 sits -31.0% from the 52-week high and -23.0% over the past 90 days, suggesting the executive is buying into a materially depressed valuation window. The company reports solid fundamentals: $5.1B revenue, $389.0M net income, 4.8% year-over-year growth, and a P/E of 14.49, all consistent with a stable healthcare technology business. This transaction adds to the signal that leadership views current levels as an opportunity, though the magnitude of the purchase (1.8K shares, $105.8K) is modest relative to his total holdings and cannot be generalized as a large-scale conviction bet.

Kenneth R. Stacherski (Chief Supply Chain Officer) sold 19,008 shares of GEHC at $83.22 on 2024-08-14, reducing holdings by 33.0% to 38.5K shares.

Kenneth R. Stacherski, Chief Supply Chain & Services Officer, executed a substantial sale of 19,008 shares at $83.22, representing a one-third reduction in his recorded holdings to 38.5K shares. The transaction occurred at a price approximately 2.4% below the current market price of $85.30 and approximately 11.3% below the 52-week high of $93.87, positioning the trade within typical historical price ranges for the stock. GE HealthCare has demonstrated modest near-term positive momentum (3.2% gain over 30 days) alongside solid quarterly fundamentals including $4.8B in revenue and annual growth of 6.6%, though the company trades at a relatively elevated P/E multiple of 24.65. The magnitude of this sale—disposing of one-third of holdings in a single transaction—merits standard monitoring but lacks contextual signals of acute concern given the company's stable financial position and the trading price's proximity to recent historical norms.